textabstractFlecainide acetate has been shown to be a potent antiarrhythmic agent which is active for more than 8 h, whether given intravenously or orally. However, the negative inotropic effect demonstrated in animal studies could hamper the potential clinical utility of the drug. Ten patients with coronary artery disease but without cardiac failure were given intravenous flecainide (2 mg/kg). Stroke index (SI), left ventricular systolic pressure (LVP), end diastolic pressure (EDP) and LV contractility indices (max dP/dt, VCE 40 mm Hg, peak VCE, Vmax from total pressure (TP] were measured immediately before and 10 min after flecainide, under resting conditions and during atrial pacing with heart rates up to 133 +/- 4.2 beats/min (mean +/- ...
OBJECTIVES The aim of the study was to evaluate the effects of intravenous (IV) flecainide on defibr...
Over the last 35 years, flecainide proved itself one of the most commonly used arrhythmic drugs, exp...
class I arrhythmics, antiarrhythmic drug combinations possible and to be avoided. Negative inotropic...
The hemodynamic effects of flecainide acetate, a new class I antiarrhythmic agent, were studied in 1...
The haemodynamic effects of flecainide were compared in three different subsets of patients with doc...
textabstractThe haemodynamic effects of encainide, flecainide, lorcainide and tocainide in man are r...
textabstractEpicardial marker motion was measured in 14 patients before flecainide administration, i...
Thirty-eight patients with organic heart disease and history of sudden cardiac arrest or recurrent s...
It is imperative to develop better approaches to predict how antiarrhythmic drugs with multiple inte...
International audienceFlecainide is a class Ic antiarrhythmic agent that has an important role as pa...
Flecainide has demonstrated unsurpassed antiarrhythmic activity in patients with stable ventricular ...
This study compared the in vitro versus in vivo effects of flecainide on effective refractory period...
Effective antiarrhythmic therapy requires a carefully considered approach, including an understandin...
The electrophysiologic properties of flecainide, a new potent antiarrhythmic drug, are poorly define...
AbstractFlecainide is effective against certain supraventricular arrhythmias (atrial fibrillation an...
OBJECTIVES The aim of the study was to evaluate the effects of intravenous (IV) flecainide on defibr...
Over the last 35 years, flecainide proved itself one of the most commonly used arrhythmic drugs, exp...
class I arrhythmics, antiarrhythmic drug combinations possible and to be avoided. Negative inotropic...
The hemodynamic effects of flecainide acetate, a new class I antiarrhythmic agent, were studied in 1...
The haemodynamic effects of flecainide were compared in three different subsets of patients with doc...
textabstractThe haemodynamic effects of encainide, flecainide, lorcainide and tocainide in man are r...
textabstractEpicardial marker motion was measured in 14 patients before flecainide administration, i...
Thirty-eight patients with organic heart disease and history of sudden cardiac arrest or recurrent s...
It is imperative to develop better approaches to predict how antiarrhythmic drugs with multiple inte...
International audienceFlecainide is a class Ic antiarrhythmic agent that has an important role as pa...
Flecainide has demonstrated unsurpassed antiarrhythmic activity in patients with stable ventricular ...
This study compared the in vitro versus in vivo effects of flecainide on effective refractory period...
Effective antiarrhythmic therapy requires a carefully considered approach, including an understandin...
The electrophysiologic properties of flecainide, a new potent antiarrhythmic drug, are poorly define...
AbstractFlecainide is effective against certain supraventricular arrhythmias (atrial fibrillation an...
OBJECTIVES The aim of the study was to evaluate the effects of intravenous (IV) flecainide on defibr...
Over the last 35 years, flecainide proved itself one of the most commonly used arrhythmic drugs, exp...
class I arrhythmics, antiarrhythmic drug combinations possible and to be avoided. Negative inotropic...